RESCEU (REspiratory Syncytial virus Consortium in EUrope)

The RESCEU project aims to develop robust evidence on respiratory syncytial virus (RSV) disease burden and economic impact in Europe and provide infrastructure to perform future pivotal clinical trials for RSV vaccines and therapeutics.

Image
RESCEU research programme logo Respiratory Syncital Virus Consortium Europe

Summary (Research in a nutshell)

Human respiratory syncytial virus (RSV) is a viral infection which can cause severe respiratory disease in the very young, elderly and in high risk groups such as premature babies or adults with chronic obstructive lung disease.

RESCEU project is an Innovative Medicines Initiative (IMI) funded project under the EU’s Horizon 2020 programme and has been funded for 5 years from 2017 to 2021. It comprises six work packages.

Using a multidisciplinary and international approach, RESCEU brings together clinicians, epidemiologists, scientists, health economists, statisticians, public health professionals, patient organisations, regulatory agencies and industry to address key gaps in knowledge of RSV. The project is timely given the many RSV vaccines and therapeutics currently under development.

Key People

NameRole
Professor Harish NairProfessor of Paediatric Infectious Diseases and Global Health, Project Coordinator
Professor Harry CampbellProfessor of Genetic Epidemiology and Public Health
Rachel ReevesResearch Fellow
Ting ShiResearch Fellow
Anne DouglasResearch Fellow
Stephanie ScottResearch Assistant
You LiPhD student
Professor Steve CunninghamProfessor of Paediatric Respiratory Medicine (based in Centre for Inflammation Research)
Professor Debby BogaertScottish Senior Clinical Fellow and Honorary Consultant in paediatric infectious diseases (based in Centre for Inflammation Research)

Contact

Professor Harish Nair: harish.nair@ed.ac.uk

Website

www.resc-eu.org

Key publications

No publications yet.

Key Collaborations

ECDC (European Centre for Disease Control)

WHO (World Health Organisation)

GIHSN (Global Influenza Hospitalisation Surveillance Network)

RSV GEN (RSV Global Epidemiology Network)

ReSViNet (Respiratory Syncytial Virus Network)

Partners

University of Antwerp, Belgium

University Medical Centre Utrecht, Netherlands

University of Oxford, UK

Synapse Research Management Partners S.L, Spain

Imperial College of Science, Technology and Medicine, UK

Servicio Galego de Saúde, Spain

Varsinais-Suomen sairaanhoitopiirin kuntayhtymä, Finland

Rijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment),  Netherlands

Statens Serum Institut, Denmark

Academisch Ziekenhuis Groningen, Netherlands

Fondazione PENTA, Italy

AstraZeneca AB

Pfizer Limited

GlaxoSmithKline Biologicals SA

Sanofi Pasteur

Janssen Pharmaceutica NV

Novavax Inc.

Funders

Innovative Medicines Initiative 2 Joint Undertaking

European Union’s Horizon 2020 research and innovation programme and EFPIA (Grant no. 1156019)

Timeline

January 2017- December 2021

 

Scientific themes

Respiratory Syncytial Virus, respiratory infections, epidemiology, burden of disease, clinical trials

Methodology keywords

Systematic review, clinical trial, biobank, record-linkage, epidemiology, health economics, modelling